Innovent Biologics (HKSE:01801) Change In Working Capital : HK$441 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics Change In Working Capital?

Innovent Biologics's change in working capital for the quarter that ended in Dec. 2023 was HK$853 Mil.

Innovent Biologics's change in working capital for the fiscal year that ended in Dec. 2023 was HK$441 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Innovent Biologics Change In Working Capital Historical Data

The historical data trend for Innovent Biologics's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Change In Working Capital Chart

Innovent Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-157.19

-396.00

-112.63

346.08

441.22

Innovent Biologics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Working Capital	Get a 7-Day Free Trial										365.25	203.80	151.93	-411.56	852.77

Innovent Biologics Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$441 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Innovent Biologics Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics (HKSE:01801) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (HKSE:01801) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

IVBXF:USA IVBIY:USA 6IB:Germany

Address

168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.innoventbio.com

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Executives

Jpmorgan Chase & Co.	2502 Approved lending agent
Yu De-chao Michael	2101 Beneficial owner
Temasek Holdings (private) Limited
Brown Brothers Harriman & Co.	2502 Approved lending agent
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Morgan Stanley	2201 Interest of corporation controlled by you
Citigroup Inc.	2201 Interest of corporation controlled by you
Shi Yi	2201 Interest of corporation controlled by you
Lav Asset Management (hong Kong) Limited	2102 Investment manager
Eight Roads Investments	2101 Beneficial owner
Fullerton Management Pte Ltd	2201 Interest of corporation controlled by you
Temasek Life Sciences Private Limited	2201 Interest of corporation controlled by you
Tls Beta Pte. Ltd.	2101 Beneficial owner

Innovent Biologics (HKSE:01801) Headlines

No Headlines